Immucell Corp /De/ financial data

Symbol
ICCC on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
56 Evergreen Dr, Portland, ME
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 280 % -27.8%
Quick Ratio 182 % -0.14%
Debt-to-equity 74.8 % +44%
Return On Equity -16.3 % +20.3%
Return On Assets -9.35 % +30.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.83M shares +1.11%
Common Stock, Shares, Outstanding 7.83M shares +1.11%
Entity Public Float 31.2M USD -51.6%
Common Stock, Value, Issued 790K USD +1.05%
Weighted Average Number of Shares Outstanding, Basic 7.81M shares +0.82%
Weighted Average Number of Shares Outstanding, Diluted 7.81M shares +0.82%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 5.4M USD +12.5%
Research and Development Expense 4.48M USD -1.13%
Selling and Marketing Expense 3.27M USD -1.32%
General and Administrative Expense 2.17M USD +1.18%
Operating Income (Loss) -3.87M USD +33.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.05M USD +32.7%
Income Tax Expense (Benefit) 4.26K USD -49.5%
Net Income (Loss) Attributable to Parent -4.05M USD +32.7%
Earnings Per Share, Basic -0.53 USD/shares +32.1%
Earnings Per Share, Diluted -0.53 USD/shares +32.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.32M USD
Cash, Cash Equivalents, and Short-term Investments 11.8M USD +73.6%
Accounts Receivable, after Allowance for Credit Loss, Current 1.95M USD +30.1%
Inventory, Net 7.3M USD -3.14%
Other Assets, Current 57.7K USD -24.8%
Assets, Current 10.8M USD -1.39%
Property, Plant and Equipment, Net 26.4M USD -7.54%
Operating Lease, Right-of-Use Asset 4.5M USD +5.08%
Intangible Assets, Net (Excluding Goodwill) 43K USD -30.8%
Goodwill 95.6K USD 0%
Other Assets, Noncurrent 37.7K USD -54.3%
Assets 41.9M USD -4.89%
Liabilities, Current 4.56M USD +8.68%
Long-term Debt and Lease Obligation 9.8M USD
Operating Lease, Liability, Noncurrent 4.04M USD -6.29%
Liabilities 18.4M USD +7.29%
Retained Earnings (Accumulated Deficit) -14M USD -40.8%
Stockholders' Equity Attributable to Parent 23.5M USD -12.7%
Liabilities and Equity 41.9M USD -4.89%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 419K USD
Net Cash Provided by (Used in) Financing Activities -367K USD -149%
Net Cash Provided by (Used in) Investing Activities -70.4K USD +89.7%
Common Stock, Shares Authorized 15M shares 0%
Common Stock, Shares, Issued 7.9M shares +1.05%
Common Stock, Par or Stated Value Per Share 0.1 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.32M USD -8.94%
Interest Paid, Excluding Capitalized Interest, Operating Activities 136K USD +55%
Deferred Tax Assets, Valuation Allowance 4.03M USD +48.9%
Deferred Tax Assets, Gross 665K USD +752%
Operating Lease, Liability 4.58M USD +4.8%
Depreciation 2.69M USD +5.28%
Payments to Acquire Property, Plant, and Equipment 70.4K USD -89.7%
Lessee, Operating Lease, Liability, to be Paid 8.02M USD
Property, Plant and Equipment, Gross 46.2M USD +0.98%
Operating Lease, Liability, Current 533K USD +921%
Lessee, Operating Lease, Liability, to be Paid, Year Two 350K USD +3.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 712K USD +362%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +15.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.44M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 357K USD +4.04%
Deferred Tax Assets, Operating Loss Carryforwards 3.73M USD +14.5%
Current Income Tax Expense (Benefit) 8.43K USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 364K USD +4.04%
Operating Lease, Payments 475K USD +366%
Additional Paid in Capital 36.2M USD +0.9%
Amortization of Intangible Assets 19.1K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 376K USD +16.7%
Interest Expense 585K USD +61.9%